ONDrugDelivery: Improving RNA therapeutic targeting beyond delivery, with Fiona McLaughlin

Dr Fiona McLaughlin (Head of R&D) walks through the key scientific themes from her recent OnDrugDelivery article, including why most RNA therapeutics only reach a single organ today and why solid tumours require multi-target, multi-cargo delivery to make a meaningful impact for patients.

Fiona also explains how silica nanoparticles like Nuvec® are being engineered to deliver different treatments to multiple tumour cell types at once, a potential step forward in tackling tumour heterogeneity and drug resistance.

We encourage you to read the full article and submit any questions you’d like the team to address. Navigate to pages 56-58 for N4's feature: